Postoperative adjuvant immunotherapy for pathological stage II–IVa esophageal squamous cell carcinoma after radical surgery does not improve disease-free recurrence rates
Background/objectivesPostoperative adjuvant therapy for esophageal squamous cell carcinoma (ESCC) primarily includes chemotherapy and chemoradiotherapy. The survival benefits of postoperative adjuvant therapy for R0-resected ESCC remain controversial. Immunotherapy is being gradually applied periope...
Na minha lista:
| Principais autores: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2024-12-01
|
| Serier: | Frontiers in Medicine |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1517001/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
